121 related articles for article (PubMed ID: 6164559)
21. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
Kovach JS; Schutt AJ; Moertel CG; O'Connell MJ
Cancer Treat Rep; 1979; 63(11-12):1909-12. PubMed ID: 526923
[TBL] [Abstract][Full Text] [Related]
22. First clinical experiences with a selective chemotherapy of hepatocellular carcinoma with 5-fluorouridine in combination with other antipyrimidines.
Pausch J; Holstege A; Anukarahanonta T; Keppler D; Gerok W
Adv Enzyme Regul; 1985; 24():429-34. PubMed ID: 2424285
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of PALA in hypernephroma and urinary bladder cancer.
Natale RB; Yagoda A; Kelsen DP; Gralla RJ; Watson RC
Cancer Treat Rep; 1982 Dec; 66(12):2091-2. PubMed ID: 7139651
[No Abstract] [Full Text] [Related]
24. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
Moyer JD; Smith PA; Levy EJ; Handschumacher RE
Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293
[TBL] [Abstract][Full Text] [Related]
25. Phase II evaluation of PALA in patients with advanced head and neck cancer.
Creagan ET; Nichols WC; O'Fallon JR
Cancer Treat Rep; 1981; 65(9-10):827-9. PubMed ID: 7273014
[No Abstract] [Full Text] [Related]
26. Phase I trial of N-(phosphonacetyl)-L-aspartate.
Erlichman C; Strong JM; Wiernik PH; McAvoy LM; Cohen MH; Levine AS; Hubbard SM; Chabner BA
Cancer Res; 1979 Oct; 39(10):3992-5. PubMed ID: 157801
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of tyrosine aminotransferase induction by UTP deficiency and its reversal by 5-fluorouridine in cultured hepatoma cells.
Giesen EM; Beck G; Holstege A; Keppler DO
Biochim Biophys Acta; 1981 Aug; 655(1):34-40. PubMed ID: 6167286
[TBL] [Abstract][Full Text] [Related]
28. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
[TBL] [Abstract][Full Text] [Related]
29. Enzyme pattern-directed chemotherapy. Effects of antipyrimidine combinations on the ribonucleotide content of hepatomas.
Lui MS; Jackson RC; Weber G
Biochem Pharmacol; 1979 Apr; 28(7):1189-95. PubMed ID: 444276
[No Abstract] [Full Text] [Related]
30. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of PALA in advanced large bowel carcinoma.
Rubin J; Purvis J; Britell JC; Hahn RG; Moertel CG; Schutt AJ
Cancer Treat Rep; 1981; 65(3-4):335-6. PubMed ID: 6453645
[No Abstract] [Full Text] [Related]
32. Phase II evaluation of PALA in patients with metastatic lung cancer.
Creagan ET; Eagan RT; Fleming TR; Frytak S; Nichols WC; Ingle JN; Kvols LK
Cancer Treat Rep; 1981; 65(3-4):356-7. PubMed ID: 7237459
[No Abstract] [Full Text] [Related]
33. Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars.
Peters GJ; Laurensse E; Lankelma J; Leyva A; Pinedo HM
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1425-31. PubMed ID: 6542012
[TBL] [Abstract][Full Text] [Related]
34. Uridine triphosphate deficiency, growth inhibition, and death in ascites hepatoma cells induced by a combination of pyrimidine biosynthesis inhibition with uridylate trapping.
Keppler DO
Cancer Res; 1977 Mar; 37(3):911-7. PubMed ID: 189918
[TBL] [Abstract][Full Text] [Related]
35. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
Creagan ET; Ahmann DL; Ingle JN; Purvis JD; Green SJ
Cancer Treat Rep; 1981; 65(1-2):169. PubMed ID: 6894400
[No Abstract] [Full Text] [Related]
36. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
Friedman J; Moore EC; Hall SW; Loo TL
Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
[TBL] [Abstract][Full Text] [Related]
37. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Erlichman C
Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
[TBL] [Abstract][Full Text] [Related]
38. Modulation of the activity of PALA by dipyridamole.
Chan TC; Young B; King ME; Taetle R; Howell SB
Cancer Treat Rep; 1985 Apr; 69(4):425-30. PubMed ID: 3857969
[TBL] [Abstract][Full Text] [Related]
39. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
Moore EC
Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
Kensler TW; Reck LJ; Cooney DA
Cancer Res; 1981 Mar; 41(3):905-9. PubMed ID: 7459876
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
